(Alliance News) - Biotechnology-focused venture capital firm Arix Bioscience PLC on Monday said portfolio company Imara Inc has filed a registration statement for a proposed US float.
Imara filed statement with the US Securities & Exchange Commission for a proposed initial public offering on the Nasdaq Global Market.
Imara is developing treatments for sickle cell disease, including current candidate IMR-687. Early clinical data in sickle cell disease patients showed IMR-687 might improve outcomes.
All shares sold in the IPO will be offered by Imara, with "no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering".
Shares in Arix were down 1.0% at 86.16 pence in London on Monday afternoon.
By Anna Farley; annafarley@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.